v3.23.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 48,741 $ 92,942
Short-term investments 156,666 149,877
Restricted cash 146 146
Accounts receivable 397 40,221
Inventories 5,340 1,586
Other current assets 12,892 10,308
Total current assets 224,182 295,080
Property and equipment, net 5,852 6,300
Operating lease assets 65,143 68,022
Other assets 6,906 7,018
Total assets 302,083 376,420
Current liabilities:    
Accounts payable 5,068 6,871
Accrued compensation 8,913 17,659
Accrued research and development expenses 23,766 24,992
Deferred revenue 9,924 8,000
Other current liabilities 20,205 21,394
Total current liabilities 67,876 78,916
Deferred revenue - long-term 78,041 77,000
Operating lease liabilities - long-term 54,918 58,064
Liability related to the sale of future revenues - long-term 31,111 30,236
Other long-term liabilities 5,177 5,564
Total liabilities 237,123 249,780
Commitments and contingencies (Note 8)
Stockholders’ equity:    
Common stock-$0.0001 par value, 500,000 shares authorized as of March 31, 2023 and December 31, 2022; 96,538 and 95,927 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively 10 10
Additional paid-in capital 1,833,982 1,821,721
Accumulated other comprehensive (loss) income (1,237) (2,067)
Accumulated deficit (1,767,795) (1,693,024)
Total stockholders’ equity 64,960 126,640
Total liabilities and stockholders’ equity $ 302,083 $ 376,420

Source

10-Q
HTML PDF
XBRL
ZIP